and Services Administration to report program-specific information on the performance of transplant programs. Following a consensus conference in 2012, SRTR developed a new version of the public website to improve public reporting of often complex metrics, including changing from a 3-tier to a 5-tier summary metric for first-year posttransplant survival. After its release in December 2016, the new presentation was moved to a "beta" website to allow collection of additional feedback. SRTR made further improvements and released a new beta website in May 2018. In response to feedback, SRTR added 5-tier summaries for standardized waitlist mortality and deceased donor transplant rate ratios, along with an indicator of which metric most affects survival after listing. Presentation of results was made more understandable with input from patients and families from surveys and focus groups. Room for improvement remains, including continuing to make the data more useful to patients, deciding what additional data elements should be collected to improve risk adjustment, and developing new metrics that better reflect outcomes most relevant to patients.
| INTRODUC TI ON
The Scientific Registry of Transplant Recipients (SRTR) is man- 
| WHY DOE S THE SCIENTIFIC REG IS TRY OF TR AN S PL ANT RECIPIENTS PRODUCE PROG R AM -S PECIFI C REP ORTS?
The National Organ Transplantation Act (NOTA; Public Law 98-507)
of 1984 provides the legal authority for the US Department of Health and Human Services (HHS) to regulate solid organ transplantation in the United States. 3 Regarding data collection, NOTA states: • The Contractor shall disseminate for free over the internet the timely and accurate program-specific information on the performance of transplant programs according to 121.11(b) of the OPTN Final Rule.
• The transplant program information shall include waitlist data, pretransplant outcomes, acceptance and utilization of organs, and posttransplant outcomes.
• Transplant programs and OPOs with better or worse outcomes shall be identified."
| ARE THE DATA G OOD ENOUG H TO A SS E SS THE PERFORMAN CE OF PROG R AMS?
It is possible that collecting additional or better data would improve SRTR risk-prediction models. Studies have shown that data from other sources can improve risk-prediction models, 5, 6 but whether collecting these data would yield substantive changes in the PSR models or substantially affect expected program outcomes is unclear. In addition, because a data element can be added to a model does not mean it should be (for example, a debate in healthcare centers on whether analyses should be adjusted for socioeconomic variables, eg, race/ethnicity). Some argue that such adjustments allow providers to avoid taking extra steps to provide care that our most challenging patients require. 7 OPTN has established a Data Advisory Committee (DAC), and one of its charges is to develop procedures for adding data elements to the OPTN data collection system.
| ARE THE S TATIS TI C AL MODEL S G OOD ENOUG H TO A SS E SS PROG R AM PERFORMAN CE?
A common criticism is that the C-statistics for models predicting posttransplant outcomes are low. 8 However, the C-statistics for PSR models generally compare favorably to those for other healthcare outcomes prediction models. plant survival, a C-statistic of 1.00 would imply that the model assigned less risk to every recipient whose graft survived to 1 year than to every recipient whose graft failed before 1 year. The Cstatistics for the PSR models ranged from 0.66 to 0.76 for kidney models and from 0.67 to 0.83 for heart models. 12 The C-statistic, however, is not necessarily a good way to assess how well models predict transplant program performance. 13 To perform well, the models must predict the aggregate number of events for each program, not distinguish between pairs of patients.
SRTR builds the risk-adjustment models using a process designed to achieve the highest possible predictive performance given the data as measured by minimizing the cross-validation error. These models examine multiple variables collected in the OPTN data and attempt to identify the appropriate association of all predictors with posttransplant outcomes by considering flexible linear splines for continuous predictors. 
| ARE 1-YE AR PATIENT AND G R AF T SURVIVAL ADEQUATE ME A SURE S OF PROG R AM PERFORMAN CE?
There are several arguments against using outcomes with longer Receiving a kidney at a program with lower than expected posttransplant graft survival is usually better than remaining on the waiting list. 14 Therefore, SRTR is adding new measures that reflect the likelihood that patients who are listed at a program will undergo transplant, so-called pretransplant metrics. [15] [16] [17] [18] In particular, the new beta website includes 5-tier assessments of waitlist mortality rates and transplant rates based on the standardized mortality rate ratio and standardized transplant rate ratio as presented in the full PSRs. Programs may rightly note that transplant rates depend on local supply of and demand for organs, and a program may have little direct control over these factors. However, a high transplant rate is a benefit to patients irrespective of the underlying reasons. Thus, prominently reporting this information is in patients' interest.
| WHY DOE S S RTR US E TIER S A S A SUMMARY ME TRI C R ATHER THAN OTHER S TATIS TIC AL ME A SURE S?
The information on the SRTR website is designed to be accessible and understandable to patients and their families. SRTR has followed advice from the Agency for Healthcare Research and Quality (AHRQ) Best
Practices in Public Reporting. 19 AHRQ recommends using visual icons rather than numbers, and especially avoiding technical reporting with confidence intervals and other statistical measures. In addition to following the AHRQ recommendations, some SRTR investigators obtained a grant from AHRQ and have been conducting surveys and focus groups to determine optimal presentation of transplant program information. Prior to the use of 5tiers, SRTR received many inquiries from patients asking for explanations as they struggled to interpret SRTR data reports. 20 
| WHY D ID S RTR CHANG E FROM A 3-TIER R ATING SYS TEM TO A 5-TIER R ATING S YS TEM?
The old 3-tier system did not adequately differentiate transplant program performance. For example, in the January 2017 PSRs, the 3-tier system rated "as expected" 98.4% of heart, 93.6% of kidney, 97.6% of liver, and 97.0% of lung programs (Table 1) . Under the 3-tier system, program graft failure rates varied almost 4-fold within the "as expected" tier. The 5-tier system better achieves the goals of the Final
Rule by better differentiating program performance, ie, reducing the intra-tier variation in outcomes by 80% (reduced sum-of-squares). 
| ARE D IFFEREN CE S B E T WEEN THE TIER S CLINI C ALLY RELE VANT ?
What is or is not clinically relevant is subjective. However, for heart, kidney, liver, and lung programs, respectively, there are 3.4-, 3.4-, 2.9-, and 3.3-fold differences in the rates of first-year graft failure between tier 1 and tier 5 programs (Table 2) . 21 Translating these relative risks to the absolute risk scale, predicted first-year graft survival for kidney transplant recipients ranges from 93% to 97% at tier 1 and tier 5 programs, respectively, a difference of 4 percentage points. For other organs, the differences on the absolute scale are more pronounced given higher overall failure rates. For example, the difference between tier 1 and tier 5 programs for predicted first-year liver survival is 9% (85% and 94% for tier 1 and tier 5 programs, respectively); differences are 11% (85% and 96%) for heart programs and 14% (80% and 94%) for lung programs. Although some differences may seem minor, when all else is equal, minimizing any risk of posttransplant complications is likely relevant to patients.
| DO PS R RE SULTS C AUS E PROG R AMS TO AVOID HI G H -RIS K DONOR S AND PATIENTS?
Programs are not more likely to be ranked lower if they perform transplants with higher measured risk. 22 Of course, programs that have poor outcomes with high-risk transplants should seek ways to improve these outcomes. But programs that are capable of performing higher-risk transplants can do so without fear of negatively affecting their performance evaluations. Nevertheless, an informal poll of transplant management personnel at a national meeting purported to show risk aversion caused by low PSR 3-tier performance ratings. 23 Of 63 responders, 55% had had low or near-low performance ratings at their programs in the past 3 years, and personnel at lowperforming programs were more likely to indicate that they restricted selection of candidates (81% vs 38%, P = .001) and donors (77% vs 31%, P < .001). Schold et al also reported that among 23% of transplant programs with at least 1 low PSR performance rating over a 3-year period, there was a mean decline of 22.4 transplants compared with an increase of 7.8 transplants among the other programs. 24 Overall, the number of transplants has been increasing in the United States despite concerns that reporting program outcomes causes programs to reduce their transplant numbers. 25 Over the past several years, the number of kidneys retrieved for transplant that have not been transplanted (ie, have been "discarded") has increased. 26 In particular, the number of discards increased in the 2 years since implementation of the new kidney allocation system (KAS). Discards of kidneys with Kidney Donor Profile Index (KDPI) above 85% also increased more rapidly in the 2 years since KAS implementation.
However, over 80% of the increase in the discard rate can be explained by changes in the donor population rather than changes in program acceptance practices. 27 The proportion of transplants using high-KDPI kidneys declined from 10.7% in 2005% to 7.9% in 2016.
Clearly, more should be done to discourage discards, many of which are likely suitable for transplant, and transplant programs should be instructed that PSR adjustment models protect their outcomes from adverse effects due to transplanting high-KDPI kidneys. 22 
| DO CHANG E S IN TIER S OVER TIME IND I C ATE THAT TIER S DO NOT PRED I C T OUTCOME S?
In a recent brief communication, Schold et al examined changes over time in 5-tier program ratings based on 1-year graft survival. 28 Due to a substantial lag between listing and transplant, the tier assigned to a program at listing may not accurately reflect survival after transplant. Over 10 consecutive PSRs from June 2012 to December 2016, these authors found that ratings were "highly volatile," and that this implied that the ratings were of limited utility. However, they did not report how well the ratings actually predicted subsequent outcomes after transplant.
The 5-tier ratings were explicitly designed to better differentiate program outcomes by narrowing the variance in outcomes between programs within the same tier. In addition, with 4tier boundaries rather than 2, it is not surprising that 5-tier ratings would be more likely to change over time than 3-tier ratings. In addition, if low ratings encourage programs to improve their outcomes, a change (improvement) in ratings would be an intended, desirable outcome. SRTR is currently examining how well the 5tiers predicted posttransplant graft survival, arguably a better approach than examining how often programs move from 1 tier to another tier over time. The new version of the SRTR beta site also provides data indicating which outcome (waitlist mortality, transplant rate, or posttransplant graft survival) is most relevant to prospective patient survival after listing, and demonstrates that the ratings correlate with survival after listing.
| DOE S S RTR TELL OVER S I G HT BOD IE S WHI CH PROG R AMS NEED FURTHER SCRUTINY ?
SRTR makes data available for everyone, restricting only identifica- Ongoing assessment of what data elements should be included in OPTN data collection is necessary to optimize risk adjustment in the PSR models. 29 The DAC should work with OPTN's organ- 
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Measuring survival after listing may encourage best practices in waitlist management.
Although the focus of this review has been on the PSRs, SRTR also produces reports on the 58 OPOs in the United States. Much work remains to better define eligible donors and efficiencies in organ procurement and utilization. Indeed, the growing rate of deceased donor organs procured for transplant but not transplanted ("discards") is the subject of growing concern and scrutiny.
| SUMMARY
As mandated by NOTA, the Final Rule, and the SRTR contract with HRSA, SRTR has altered the way it publicly reports transplant pro- 
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